It has not been established that extended lymph node resection is necessary for @entity420 of the head of the pancreas. According to the general rules for the study of @entity788 , a multiinstitutional, retrospective clinical study was undertaken to investigate the efficiency of extended lymph node dissection for this @entity5 . Altogether 501 @entity1 underwent resection of the pancreas between 1991 and 1994 at 77 medical facilities; the surgical procedures, staging, lymph node dissection, curability, and survival rate were analyzed retrospectively. Eighteen of the @entity1 died within 30 postoperative days, leaving 483 @entity1 to be studied. The resection was curative microscopically in 94 @entity1 , resulting in a 3-year survival of 29%. Macroscopically curative resection resulted in a 3-year survival of 14%; noncurative resection produced a 3-year survival of 6%. Although extended lymph node dissection was performed on 38 @entity1 in stage I, 42 @entity1 in stage II, 206 @entity1 in stage III, and 1 @entity1 in stage IV, there was no improvement in survival when the results were compared to those seen after standard or palliative lymph node dissection. The extent of lymph node dissection has not affected the prognosis for @entity420 of the head of the pancreas at any stage of the course of the disease. Excessive lymph node dissection in advanced cases does not necessarily lead to a favorable prognosis. The @entity1 who undergo a radical operation with an adequate lymph node dissection have longer survivals.

Lack of survival benefit of extended lymph node dissection for XXXX of the head of the pancreas: retrospective multi-institutional analysis in Japan.

@entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer'] @entity420 :: ('MESH:D000230', 'Disease') :: ['ductal adenocarcinoma']
@entity420 :: (MESH:D000230,Disease) :: ['ductal adenocarcinoma']
